Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BBT-401-1S in Active Ulcerative Colitis
NCT03800420Phase 2Terminated
- Sponsor
- Bridge Biotherapeutics
- Start
- Apr 2019
- Primary completion
- May 2020
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ulcerative colitis (UC) comparing BBT-401-1S First with Placebo First (2 arms). Primary endpoint: Change From Baseline in Total Mayo Score at Week 8. Started Apr 2019; status: terminated.
02
Drugs
BBT-401
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03800420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03800420.